Amphastar Pharmaceuticals, Inc. (AMPH) fair value analysis

Nasdaq · Updated 2026-09-07

Amphastar Pharmaceuticals, Inc. is a pharmaceutical company that develops, manufactures, and markets specialty and generic injectable pharmaceutical products. The company operates primarily in the United States, serving healthcare providers and patients through its portfolio of medications and drug delivery systems.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, AMPH is trading at more than a 25% discount to estimated fair value.

AMPH currently ranks #15 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $20.22
Sector: Healthcare
12-month range: $18.42–$27.92

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C-
Momentum grade: A
Leverage: Moderate
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range

What our data shows for AMPH

Our model validated 17 trailing price-to-earnings windows for AMPH, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $18.42–$27.92.
The 14-day relative strength index sits at a neutral 68.
4 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for AMPH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent AMPH news

TickrTrends' derived news-sentiment signal for AMPH is currently leaning positive, computed from recent coverage.

A Look at Amphastar Pharmaceuticals Inc (AMPH) After 3.3% Gain -- GF Value $35.96 vs Price $23.74 (gurufocus.com, 2026-09-03)
TickrTrends take: Amphastar Pharmaceuticals trades below its GF Value estimate, which aligns with TickrTrends' undervalued assessment for this Healthcare sector company. The gap between the current price and estimated intrinsic value suggests the stock may warrant attention from investors focused on valuation metrics. Readers tracking AMPH should monitor whether the company's fundamentals support a closer convergence toward the higher valuation benchmark over time.
Q2 Earnings Blowouts: 37 Stock That Beat Expectations (insidermonkey.com, 2026-08-08)
TickrTrends take: Amphastar Pharmaceuticals was among 37 stocks that exceeded earnings expectations in the second quarter, a performance metric that typically supports stronger valuation multiples. Given TickrTrends' current undervalued assessment of AMPH within the Healthcare sector, investors focused on valuation should monitor whether the market has fully incorporated this earnings outperformance into the company's stock price. The gap between earnings delivery and current valuation rating suggests potential recalibration may occur as market participants digest the quarter's results.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-07)
TickrTrends take: Amphastar Pharmaceuticals' Q2 2026 earnings results provide concrete data points for evaluating whether TickrTrends' undervalued assessment reflects genuine margin of safety or execution risk in a competitive pharmaceutical market. Investors reviewing the earnings call should focus on revenue trends, profitability metrics, and pipeline progress to determine if current valuation multiples appropriately discount the company's competitive position within the Healthcare sector. The earnings transcript offers the operational foundation necessary to verify whether the undervalued designation holds up against actual business performance.

What people are saying

Follow the AMPH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — AMPH's 50/200-day trend state shifted from mixed to downtrend this week, reflecting weaker near-term momentum relative to the longer-term price trajectory. Despite this technical deterioration, the stock maintains an undervalued designation based on TickrTrends' derived indicators. The downtrend development suggests investors should monitor the healthcare company's price action closely for potential support levels or confirmation of further weakness.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is AMPH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), AMPH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is AMPH's TickrTrends verdict?

AMPH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does AMPH compare to other Healthcare stocks?

AMPH ranks #15 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is AMPH overbought or oversold?

AMPH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

AMPH vs ALGN · AMPH vs ANIP · AMPH vs COO · AMPH vs DXCM · AMPH vs HALO